Literature DB >> 25877624

Editors' welcome and a working definition for a multiple sclerosis cure.

Brenda Banwell, Gavin Giovannoni, Christopher Hawkes, Fred Lublin.   

Abstract

Year:  2013        PMID： 25877624     DOI： 10.1016/j.msard.2012.12.001

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  16 in total

1.  Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Authors:  Maria Pia Amato; Antonio Bertolotto; Roberto Brunelli; Paola Cavalla; Benedetta Goretti; Maria Giovanna Marrosu; Francesco Patti; Carlo Pozzilli; Leandro Provinciali; Nicola Rizzo; Nicola Strobelt; Gioacchino Tedeschi; Maria Trojano; Giancarlo Comi
Journal:  Neurol Sci       Date:  2017-08-02       Impact factor: 3.307

Review 2.  Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Authors:  Andrew L Smith; Jeffrey A Cohen; Le H Hua
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy.

Authors:  Lorena Lorefice; Federica Murgia; Giuseppe Fenu; Jessica Frau; Giancarlo Coghe; Maria Rita Murru; Stefania Tranquilli; Andrea Visconti; Maria Giovanna Marrosu; Luigi Atzori; Eleonora Cocco
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

4.  'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.

Authors:  Lorena Lorefice; G Coghe; G Fenu; M Porta; G Pilloni; J Frau; F Corona; V Sechi; M A Barracciu; M G Marrosu; M Pau; E Cocco
Journal:  J Neurol       Date:  2017-09-11       Impact factor: 4.849

Review 5.  Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part II. Insights from two MS cases.

Authors:  Susan J van Rensburg; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Armand V Peeters; Carel J van Heerden; Rajiv T Erasmus; Annalise E Zemlin; Merlisa C Kemp; Mariaan Jaftha; Aye Aye Khine; Felix C V Potocnik; Lindiwe Whati; Penelope Engel-Hills; Ronald van Toorn; Maritha J Kotze
Journal:  Metab Brain Dis       Date:  2021-03-12       Impact factor: 3.584

Review 6.  Pathology-supported genetic testing as a method for disability prevention in multiple sclerosis (MS). Part I. Targeting a metabolic model rather than autoimmunity.

Authors:  Susan J van Rensburg; Ronald van Toorn; Rajiv T Erasmus; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Merlisa C Kemp; Penelope Engel-Hills; Maritha J Kotze
Journal:  Metab Brain Dis       Date:  2021-04-28       Impact factor: 3.584

7.  Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.

Authors:  Przemysław Puz; Anetta Lasek-Bal
Journal:  Med Sci Monit       Date:  2016-11-10

Review 8.  Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.

Authors:  Charlotte Druart; Souraya El Sankari; Vincent van Pesch
Journal:  Patient Relat Outcome Meas       Date:  2017-12-21

Review 9.  "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.

Authors:  Gavin Giovannoni; Davorka Tomic; Jeremy R Bright; Eva Havrdová
Journal:  Mult Scler       Date:  2017-04-06       Impact factor: 6.312

10.  Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Authors:  Ludwig Kappos; Nicola De Stefano; Mark S Freedman; Bruce Ac Cree; Ernst-Wilhelm Radue; Till Sprenger; Maria Pia Sormani; Terence Smith; Dieter A Häring; Daniela Piani Meier; Davorka Tomic
Journal:  Mult Scler       Date:  2015-11-19       Impact factor: 6.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.